• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·VDRM
Share

ViaDerma, Inc. Stocks

$ 0Last Updated 26.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 123371

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

ViaDerma, Inc., a specialty pharmaceutical enterprise based in the United States, focuses on both the development and commercialization of pharmaceutical products. It also licenses its proprietary technology to other companies within the pharmaceutical sector, addressing various therapeutic areas. The company's primary offering is Vitastem, a topical antibiotic containing tetracycline, effective for treating a broad spectrum of ailments such as cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. Beyond its established products, ViaDerma is dedicated to expanding its pipeline, with ongoing development in fields including advanced topical antibiotics, antifungal treatments for toenails, diabetic amputation recovery, general acne, psoriasis, eczema, burn care, anti-aging and wrinkle-reducing formulations, medical cannabis applications, male pattern baldness, skin cancer, erectile dysfunction, and pain management. Established in 2007, the company operated as Décor Products International, Inc. until its renaming to ViaDerma, Inc. in May 2014. Its corporate operations are directed from Marina Del Rey, California.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is 'expensive' on P/E, undervalued on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.10.2026 22:38

GM will move its listing to the Nasdaq. What does this mean for its stock?

27.10.2026 21:09

Delays in ramping up 737 Max production overshadowed Boeing's revenue growth. The stock plummeted.

27.10.2026 19:50

"More Greed Than Fear": How Anthropic's Upcoming IPO Has Restored Faith in AI Stocks

27.10.2026 18:51

Mercedes No Longer Expects Profit Growth: Sales in China Plummeted by 30%

27.10.2026 18:23

Oil Prices Fall: Investors Hope for a "Diplomatic Breakthrough"

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026